TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Predictors of Antidepressant Treatment Response: The Emory CIDAR
Brief Summary: This study will compare different treatments for depression in order to identify which factors predict effectiveness, and will include a companion study which investigates combining treatments and long term effectiveness.


Options:
A: Arm Label: MBT therapy plus treatment as usual; Type: EXPERIMENTAL; Interventions: Other: Mentalization-Based Group Therapy for Adolescents | Arm Label: Treatment as usual alone; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Mentalization-Based Group Therapy for Adolescents; Assigned to Arm(s): MBT therapy plus treatment as usual
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical behavioral therapy for adolescents (DBT-A) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Intervention Type: BEHAVIORAL; Name: Dialectical behavioral therapy for adolescents (DBT-A); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): 2
C: Arm Label: Escitalopram; Type: ACTIVE_COMPARATOR; Interventions: Drug: Escitalopram | Arm Label: Duloxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Duloxetine | Arm Label: CBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive behavioral therapy (CBT) | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): Escitalopram | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy (CBT); Assigned to Arm(s): CBT
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioural Therapy, Other: Treatment as usual | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Treatment as usual | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioural Therapy; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Treatment as usual; Assigned to Arm(s): 1, 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Predictors of Antidepressant Treatment Response: The Emory CIDAR
Brief Summary: This study will compare different treatments for depression in order to identify which factors predict effectiveness, and will include a companion study which investigates combining treatments and long term effectiveness.


Options:
A: Arm Label: ASAP Treatment and Brite; Type: EXPERIMENTAL; Interventions: Behavioral: As Safe As Possible, Behavioral: Brite | Arm Label: Treatment as Usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as Usual | Intervention Type: BEHAVIORAL; Name: As Safe As Possible; Assigned to Arm(s): ASAP Treatment and Brite | Intervention Type: BEHAVIORAL; Name: Brite; Assigned to Arm(s): ASAP Treatment and Brite | Intervention Type: BEHAVIORAL; Name: Treatment as Usual; Assigned to Arm(s): Treatment as Usual
B: Arm Label: Escitalopram; Type: ACTIVE_COMPARATOR; Interventions: Drug: Escitalopram | Arm Label: Duloxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Duloxetine | Arm Label: CBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive behavioral therapy (CBT) | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): Escitalopram | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy (CBT); Assigned to Arm(s): CBT
C: Arm Label: Treatment; Type: N/A; Interventions: Behavioral: Dialectical Behavioural Therapy (DBT) | Arm Label: Waitlist; Type: N/A; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dialectical Behavioural Therapy (DBT); Assigned to Arm(s): Treatment
D: Arm Label: Dialectical Behaviour Therapy-6 months; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical Behaviour Therapy-6 months | Arm Label: Dialectical Behaviour Therapy-12 months; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dialectical Behaviour Therapy-12 months | Intervention Type: BEHAVIORAL; Name: Dialectical Behaviour Therapy-6 months; Assigned to Arm(s): Dialectical Behaviour Therapy-6 months | Intervention Type: BEHAVIORAL; Name: Dialectical Behaviour Therapy-12 months; Assigned to Arm(s): Dialectical Behaviour Therapy-12 months

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Predictors of Antidepressant Treatment Response: The Emory CIDAR
Brief Summary: This study will compare different treatments for depression in order to identify which factors predict effectiveness, and will include a companion study which investigates combining treatments and long term effectiveness.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: Behavioral: Dialectical Cognitive Therapy | Intervention Type: BEHAVIORAL; Name: Dialectical Cognitive Therapy; Assigned to Arm(s): 1
B: Arm Label: Escitalopram; Type: ACTIVE_COMPARATOR; Interventions: Drug: Escitalopram | Arm Label: Duloxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Duloxetine | Arm Label: CBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive behavioral therapy (CBT) | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): Escitalopram | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy (CBT); Assigned to Arm(s): CBT
C: Arm Label: CAMS treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Psychotherapy | Arm Label: Treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychotherapy | Intervention Type: BEHAVIORAL; Name: Psychotherapy; Assigned to Arm(s): CAMS treatment, Treatment as usual
D: Arm Label: SIC + NET; Type: EXPERIMENTAL; Interventions: Behavioral: Narrative Exposure Therapy, Behavioral: Standard Inpatient Care, Other: Waiting List | Arm Label: SIC + DBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dialectical Behavior Therapy, Behavioral: Standard Inpatient Care, Other: Waiting List | Intervention Type: BEHAVIORAL; Name: Narrative Exposure Therapy; Assigned to Arm(s): SIC + NET | Intervention Type: BEHAVIORAL; Name: Dialectical Behavior Therapy; Assigned to Arm(s): SIC + DBT | Intervention Type: BEHAVIORAL; Name: Standard Inpatient Care; Assigned to Arm(s): SIC + DBT, SIC + NET | Intervention Type: OTHER; Name: Waiting List; Assigned to Arm(s): SIC + DBT, SIC + NET

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Predictors of Antidepressant Treatment Response: The Emory CIDAR
Brief Summary: This study will compare different treatments for depression in order to identify which factors predict effectiveness, and will include a companion study which investigates combining treatments and long term effectiveness.


Options:
A: Arm Label: Mindfulness; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness | Arm Label: Interpersonal effectiveness; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: interpersonal effectiveness | Intervention Type: BEHAVIORAL; Name: Mindfulness; Assigned to Arm(s): Mindfulness | Intervention Type: BEHAVIORAL; Name: interpersonal effectiveness; Assigned to Arm(s): Interpersonal effectiveness
B: Arm Label: Escitalopram; Type: ACTIVE_COMPARATOR; Interventions: Drug: Escitalopram | Arm Label: Duloxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Duloxetine | Arm Label: CBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive behavioral therapy (CBT) | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): Escitalopram | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy (CBT); Assigned to Arm(s): CBT
C: Arm Label: Dialectical Behavior Therapy DBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DBT | Arm Label: CAMS; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CAMS | Intervention Type: BEHAVIORAL; Name: DBT; Assigned to Arm(s): Dialectical Behavior Therapy DBT | Intervention Type: BEHAVIORAL; Name: CAMS; Assigned to Arm(s): CAMS
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioural Therapy, Other: Treatment as usual | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Treatment as usual | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioural Therapy; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Treatment as usual; Assigned to Arm(s): 1, 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preventing Depression in School Children
Brief Summary: This study will evaluate the effectiveness of the Penn Resiliency Program, a school-based cognitive behavioral depression prevention program for young adolescents.


Options:
A: Intervention Type: BEHAVIORAL; Name: Early psychological intervention; Assigned to Arm(s): N/A
B: Arm Label: Mindfulness-based stress reduction; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness-based stress reduction | Arm Label: Healthy Topics; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Mindfulness-based stress reduction | Intervention Type: BEHAVIORAL; Name: Mindfulness-based stress reduction; Assigned to Arm(s): Healthy Topics, Mindfulness-based stress reduction
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavior therapy (CBT) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive/expressive (S/E) therapy | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Bibliotherapy | Arm Label: 4; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive behavior therapy (CBT); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Supportive/expressive (S/E) therapy; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Bibliotherapy; Assigned to Arm(s): 3
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Adolescent only Penn Resiliency Program (Adolescent PRP) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Adolescent only Penn Resiliency Program (Adolescent PRP), Behavioral: Parent Penn Resiliency Program (Parent PRP) | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Adolescent only Penn Resiliency Program (Adolescent PRP); Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Parent Penn Resiliency Program (Parent PRP); Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Open Label, Parallel Group, Active Control Study to Evaluate the Efficacy and Safety of LNG IUS (Mirena®) as Compared to Medroxyprogesterone Acetate During 6 Cycles of Treatment in Patients With Idiopathic Menorrhagia
Brief Summary: The purpose of this study is to determine whether the levonorgestrel-releasing intrauterine system is effective in decreasing menstrual blood loss.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic acid tablets | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic acid tablets | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo tablets | Intervention Type: DRUG; Name: Tranexamic acid tablets; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Tranexamic acid tablets; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo tablets; Assigned to Arm(s): 3
B: Arm Label: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027); Type: EXPERIMENTAL; Interventions: Drug: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027); Assigned to Arm(s): Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Levonorgestrel Intrauterine System (LNG IUS) 20µg per 24 hours; Type: EXPERIMENTAL; Interventions: Drug: Levonorgestrel IUS (Mirena, BAY86-5028) | Arm Label: Medroxyprogesterone acetate (MPA); Type: ACTIVE_COMPARATOR; Interventions: Drug: Medroxyprogesterone acetate | Intervention Type: DRUG; Name: Levonorgestrel IUS (Mirena, BAY86-5028); Assigned to Arm(s): Levonorgestrel Intrauterine System (LNG IUS) 20µg per 24 hours | Intervention Type: DRUG; Name: Medroxyprogesterone acetate; Assigned to Arm(s): Medroxyprogesterone acetate (MPA)
D: Arm Label: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027); Type: EXPERIMENTAL; Interventions: Drug: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027); Assigned to Arm(s): Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Duloxetine for Chronic Depression: a Double-blind Study
Brief Summary: The investigators are studying a new antidepressant medicine, duloxetine, for the treatment of people with chronic depression. Duloxetine (trade name Cymbalta) was recently approved by the FDA for the treatment of major depression. The investigators are testing whether this medicine is also effective for adults with chronic depression (dysthymic disorder or dysthymia).

Chronic depression, lasting two or more years, often causes significant suffering and impairment. The investigators study involves a 6 to 10 week double-blind Initial Phase during which half of the participants will take the new medication and half will take a placebo (an inactive look-alike pill). After the Initial Phase, a 12-week Continuation Phase will begin, during which all subjects can be treated with an FDA-approved antidepressant medication.

Eligible subjects may also receive MRI scans, to help the investigators understand how antidepressants work in treating depression.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Continuation phase cognitive therapy, Behavioral: Acute phase cognitive therapy | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Continuation phase pill placebo, Behavioral: Acute phase cognitive therapy | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Continuation phase fluoxetine, Behavioral: Acute phase cognitive therapy | Intervention Type: BEHAVIORAL; Name: Continuation phase cognitive therapy; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Continuation phase fluoxetine; Assigned to Arm(s): 3 | Intervention Type: OTHER; Name: Continuation phase pill placebo; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Acute phase cognitive therapy; Assigned to Arm(s): 1, 2, 3
B: Intervention Type: DRUG; Name: Venlafaxine ER; Assigned to Arm(s): N/A
C: Arm Label: duloxetine (cymbalta); Type: EXPERIMENTAL; Interventions: Drug: Duloxetine (Cymbalta) | Arm Label: Placebo treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: Duloxetine (Cymbalta) | Intervention Type: DRUG; Name: Duloxetine (Cymbalta); Assigned to Arm(s): Placebo treatment, duloxetine (cymbalta)
D: Arm Label: Behavioral Activation for Return to Work; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Activation for return to work | Intervention Type: BEHAVIORAL; Name: Behavioral Activation for return to work; Assigned to Arm(s): Behavioral Activation for Return to Work

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diabetes Control and Complications Trial (DCCT)
Brief Summary: Background. Long-term microvascular and neurologic complications cause major morbidity and mortality in patients with insulin-dependent diabetes mellitus (IDDM). We examined whether intensive treatment with the goal of maintaining blood glucose concentrations close to the normal range could decrease the frequency and severity of these complications.

Methods. A total of 1441 patients with IDDM -- 726 with no retinopathy at base line (the primary-prevention cohort) and 715 with mild retinopathy (the secondary-intervention cohort) were randomly assigned to intensive therapy administered either with an external insulin pump or by three or more daily insulin injections and guided by frequent blood glucose monitoring or to conventional therapy with one or two daily insulin injections. The patients were followed for a mean of 6.5 years, and the appearance and progression of retinopathy and other complications were assessed regularly.


Options:
A: Arm Label: Traditional Chinese Medicine; Type: ACTIVE_COMPARATOR; Interventions: Drug: TCM | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: TCM; Assigned to Arm(s): Traditional Chinese Medicine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Exenatide; Type: ACTIVE_COMPARATOR; Interventions: Drug: exenatide | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: DRUG; Name: exenatide; Assigned to Arm(s): Exenatide
C: Intervention Type: BEHAVIORAL; Name: Insulin; Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vildagliptin; Type: EXPERIMENTAL; Interventions: Drug: vildagliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): Vildagliptin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diabetes Control and Complications Trial (DCCT)
Brief Summary: Background. Long-term microvascular and neurologic complications cause major morbidity and mortality in patients with insulin-dependent diabetes mellitus (IDDM). We examined whether intensive treatment with the goal of maintaining blood glucose concentrations close to the normal range could decrease the frequency and severity of these complications.

Methods. A total of 1441 patients with IDDM -- 726 with no retinopathy at base line (the primary-prevention cohort) and 715 with mild retinopathy (the secondary-intervention cohort) were randomly assigned to intensive therapy administered either with an external insulin pump or by three or more daily insulin injections and guided by frequent blood glucose monitoring or to conventional therapy with one or two daily insulin injections. The patients were followed for a mean of 6.5 years, and the appearance and progression of retinopathy and other complications were assessed regularly.


Options:
A: Arm Label: IDeg OD ± OADs followed by IGlar OD ± OADs; Type: EXPERIMENTAL; Interventions: Drug: insulin degludec, Drug: insulin glargine | Arm Label: IGlar OD ± OADs followed by IDeg OD ± OADs; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin degludec, Drug: insulin glargine | Intervention Type: DRUG; Name: insulin degludec; Assigned to Arm(s): IDeg OD ± OADs followed by IGlar OD ± OADs, IGlar OD ± OADs followed by IDeg OD ± OADs | Intervention Type: DRUG; Name: insulin glargine; Assigned to Arm(s): IDeg OD ± OADs followed by IGlar OD ± OADs, IGlar OD ± OADs followed by IDeg OD ± OADs
B: Arm Label: insulin detemir; Type: EXPERIMENTAL; Interventions: Drug: insulin detemir, Drug: insulin aspart | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): insulin detemir | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): insulin detemir
C: Intervention Type: BEHAVIORAL; Name: Insulin; Assigned to Arm(s): N/A
D: Arm Label: IDeg OD; Type: EXPERIMENTAL; Interventions: Drug: insulin degludec, Drug: insulin aspart | Arm Label: IGlar OD; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin glargine, Drug: insulin aspart | Intervention Type: DRUG; Name: insulin degludec; Assigned to Arm(s): IDeg OD | Intervention Type: DRUG; Name: insulin glargine; Assigned to Arm(s): IGlar OD | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): IDeg OD, IGlar OD

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diabetes Control and Complications Trial (DCCT)
Brief Summary: Background. Long-term microvascular and neurologic complications cause major morbidity and mortality in patients with insulin-dependent diabetes mellitus (IDDM). We examined whether intensive treatment with the goal of maintaining blood glucose concentrations close to the normal range could decrease the frequency and severity of these complications.

Methods. A total of 1441 patients with IDDM -- 726 with no retinopathy at base line (the primary-prevention cohort) and 715 with mild retinopathy (the secondary-intervention cohort) were randomly assigned to intensive therapy administered either with an external insulin pump or by three or more daily insulin injections and guided by frequent blood glucose monitoring or to conventional therapy with one or two daily insulin injections. The patients were followed for a mean of 6.5 years, and the appearance and progression of retinopathy and other complications were assessed regularly.


Options:
A: Intervention Type: BEHAVIORAL; Name: Insulin; Assigned to Arm(s): N/A
B: N/A
C: Arm Label: Standard glycemic control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Arm Label: Intensive glycemic control; Type: EXPERIMENTAL; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control
D: Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo

Answer: A